MFC Industrial Ltd (MIL.N)
9.15USD
4:07pm EDT
$0.10 (+1.11%)
$9.05
$9.01
$9.15
$8.98
9,100
21,516
$10.35
$6.66
MIL.N
About
Overall
| Beta: | 1.43 |
| Market Cap (Mil.): | $566.10 |
| Shares Outstanding (Mil.): | 62.55 |
| Dividend: | 0.06 |
| Yield (%): | 2.65 |
Financials
| MIL.N | Industry | Sector | |
|---|---|---|---|
| P/E (TTM): | 2.27 | 33.88 | 17.25 |
| EPS (TTM): | 3.99 | -- | -- |
| ROI: | 29.59 | 2.78 | 1.40 |
| ROE: | 37.02 | 6.53 | 23.63 |
Elan CEO says shareholders unmoved by Royalty bid
DUBLIN - Elan's chief executive said he has not spoken to one shareholder who views Royalty Pharma's bid for the company as credible and that it had nothing to do with Monday's deal with fellow drugmaker Theravance.
Elan considered buying Royalty before becoming its target
DUBLIN - Elan considered buying U.S. investment firm Royalty Pharma last year, six months before Royalty made its approach for the Irish drugmaker, the offer document for the bid showed on Thursday.
UPDATE 1-Elan considered buying Royalty before becoming its target
* Royalty submits offer document, will only offer fair price
UPDATE 3-J&J stake sale clouds Royalty bid for Elan
* Royalty had urged shareholders to tender at $11.75 or $12
UPDATE 4-Royalty's sweetened offer puts pressure on Elan board
DUBLIN/NEW YORK, April 15 - Royalty Pharma's sweetened its bid for Irish drugmaker Elan, heaping pressure on its management to open its books to the U.S. investment firm in the hope of a better offer, analysts and shareholders said on Monday.
Royalty Pharma launches improved bid for Elan
DUBLIN/ NEW YORK - U.S. investment firm Royalty Pharma launched a cash offer on Monday for Elan worth up to $7.3 billion, improving on its initial proposal to take over the Irish drugmaker and the lucrative royalty rights on its main drug.
Competitors
| Price | Change | |
|---|---|---|
| GFI Group Inc. (GFIG.N) | $4.34 | 0.00 |
Earnings vs. 
Estimates
Analyst Research Reports
| Report Title | Price |
|---|---|
|
Provider: Pechala's Reports
|
$15.00
|
|
Provider: Reuters Investment Profile
|
$20.00
|
|
Provider: S&P Capital IQ Quantitative Report
|
$46.00
|
|
Provider: Wright Reports
|
$483.00
|
|
Provider: Validea
|
$12.00
|
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
Thomson Reuters is the world's largest international multimedia news agency, providing investing news, world news, business news, technology news, headline news, small business news, news alerts, personal finance, stock market, and mutual funds information available on Reuters.com, video, mobile, and interactive television platforms. Thomson Reuters journalists are subject to an Editorial Handbook which requires fair presentation and disclosure of relevant interests.
NYSE and AMEX quotes delayed by at least 20 minutes. Nasdaq delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
